Headlines about Avadel Pharmaceuticals (NASDAQ:AVDL) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Avadel Pharmaceuticals earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.7866555737049 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have impacted Accern’s scoring:
- Avadel Offers An Excellent Risk/Reward Profile (seekingalpha.com)
- Avadel Pharmaceuticals (AVDL) Upgraded to Hold at BidaskClub (americanbankingnews.com)
- Avadel Pharmaceuticals (AVDL) Stock Rating Upgraded by ValuEngine (americanbankingnews.com)
- Avadel Pharma (AVDL) Announces Acceptance of Late-Breaker Presentation for NOCTIVA at AUA (streetinsider.com)
- Avadel Pharmaceuticals Announces Acceptance of Late-Breaker Presentation for NOCTIVA™ at the 2018 American Urological Association (markets.financialcontent.com)
Several equities analysts have recently commented on the stock. BidaskClub upgraded shares of Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. ValuEngine upgraded shares of Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday. TheStreet cut shares of Avadel Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Thursday, March 8th. Ladenburg Thalmann Financial Services lowered their price objective on shares of Avadel Pharmaceuticals to $24.00 and set a “buy” rating for the company in a research report on Friday, March 9th. Finally, Zacks Investment Research upgraded shares of Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $20.00.
Avadel Pharmaceuticals (NASDAQ:AVDL) last released its quarterly earnings data on Thursday, March 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05). Avadel Pharmaceuticals had a return on equity of 15.40% and a net margin of 38.64%. The company had revenue of $34.20 million for the quarter, compared to analyst estimates of $34.16 million. The company’s revenue for the quarter was down 20.6% on a year-over-year basis. analysts predict that Avadel Pharmaceuticals will post -1.29 EPS for the current fiscal year.
Avadel Pharmaceuticals announced that its board has authorized a share buyback program on Tuesday, March 27th that allows the company to buyback $7.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 2.7% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.
TRADEMARK VIOLATION WARNING: This piece of content was reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/04/05/avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-earns-news-sentiment-score-of-0-07/2028765.html.
Avadel Pharmaceuticals Company Profile
Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria.
Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.